Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Feb;59(2):227–230. doi: 10.1038/bjc.1989.46

Combination versus sequential single agent chemotherapy in advanced breast cancer: associations with metastatic sites and long-term survival. The Western Cancer Study Group and The Southeastern Cancer Study Group.

R T Chlebowski 1, R V Smalley 1, J M Weiner 1, L E Irwin 1, A A Bartolucci 1, J R Bateman 1
PMCID: PMC2246985  PMID: 2649130

Abstract

Two hundred and twenty-two patients with advanced breast cancer were randomised in two separate trials of similar design to either concomitant combination treatment or sequential use of the same drugs given as single agents changed only at disease progression. Both trials used cyclophosphamide, methotrexate, 5-fluorouracil and prednisone; the WCSG using triiodothyronine and the SECSG using vincristine as the remaining agent. A common data base was generated for these trials and combined for analysis. Considering all patients, combination treatment was associated with a significantly increased response (46 versus 25%, P less than 0.05) but not survival improvement. For the 141 patients without liver involvement, survival was closely comparable in both treatment arms. Combination therapy did result in significant survival benefit for patients with liver involvement (P less than 0.05). These studies demonstrate: (1) in the majority of breast cancer patients, sequential single agent therapy can result in survival comparable to combination treatment; and (2) sole consideration of response frequency does not represent the optimal criterion to compare therapeutic approaches in advanced breast cancer.

Full text

PDF
230

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmann D. L., Bisel H. F., Eagan R. T., Edmonson J. H., Hahn R. G. Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer. Cancer Chemother Rep. 1974 Nov-Dec;58(6):877–882. [PubMed] [Google Scholar]
  2. Ahmann D. L., Schaid D. J., Bisel H. F., Hahn R. G., Edmonson J. H., Ingle J. N. The effect on survival of initial chemotherapy in advanced breast cancer: polychemotherapy versus single drug. J Clin Oncol. 1987 Dec;5(12):1928–1932. doi: 10.1200/JCO.1987.5.12.1928. [DOI] [PubMed] [Google Scholar]
  3. Aisner J., Weinberg V., Perloff M., Weiss R., Perry M., Korzun A., Ginsberg S., Holland J. F. Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B. J Clin Oncol. 1987 Oct;5(10):1523–1533. doi: 10.1200/JCO.1987.5.10.1523. [DOI] [PubMed] [Google Scholar]
  4. Baker L. H., Vaughn C. B., al-Sarraf M., Reed M. L., Vaitkevicius V. K. Proceedings: Evaluation of combination vs. sequential cytotoxic chemotherapy in the treatment of advanced breast cancer. Cancer. 1974 Feb;33(2):513–518. doi: 10.1002/1097-0142(197402)33:2<513::aid-cncr2820330228>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  5. Chemotherapy versus hormonal therapy in advanced breast carcinoma. N Engl J Med. 1986 Oct 23;315(17):1092–1093. doi: 10.1056/NEJM198610233151712. [DOI] [PubMed] [Google Scholar]
  6. Chlebowski R. T., Irwin L. E., Pugh R. P., Sadoff L., Hestorff R., Wiener J. M., Bateman J. R. Survival of patients with metastatic breast cancer treated with either combination or sequential chemotherapy. Cancer Res. 1979 Nov;39(11):4503–4506. [PubMed] [Google Scholar]
  7. Chlebowski R. T., Weiner J. M., Ryden V. M., Bateman J. R. Factors influencing the interim interpretation of a breast cancer trial: danger of achieving the "expected" result. Control Clin Trials. 1981 Jun;2(2):123–132. doi: 10.1016/0197-2456(81)90003-9. [DOI] [PubMed] [Google Scholar]
  8. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 Sep;7(3):177–188. doi: 10.1016/0197-2456(86)90046-2. [DOI] [PubMed] [Google Scholar]
  9. Elashoff J. D. Combining results of clinical trials. Gastroenterology. 1978 Dec;75(6):1170–1172. [PubMed] [Google Scholar]
  10. GREENSPAN E. M., FIEBER M., LESNICK G., EDELMAN S. Response of advanced breast carcinoma to the combination of the antimetabolite, Methotrexate, and the alkylating agent, thio-TEPA. J Mt Sinai Hosp N Y. 1963 May-Jun;30:246–267. [PubMed] [Google Scholar]
  11. Hayes D. F., Henderson I. C. CAF in metastatic breast cancer: standard therapy or another effective regimen? J Clin Oncol. 1987 Oct;5(10):1497–1499. doi: 10.1200/JCO.1987.5.10.1497. [DOI] [PubMed] [Google Scholar]
  12. Kieser R., Conrad B. Randomized clinical trials in breast cancer: a tabular summary. Part 2: Advanced breast cancer. Arch Geschwulstforsch. 1987;57(4):323–349. [PubMed] [Google Scholar]
  13. LEMON H. M. Cortisone-thyroid therapy of metastatic mammary cancer. Ann Intern Med. 1957 Mar;46(3):457–484. doi: 10.7326/0003-4819-46-3-457. [DOI] [PubMed] [Google Scholar]
  14. Levine M. N., Gent M., Hirsh J., Arnold A., Goodyear M. D., Hryniuk W., De Pauw S. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med. 1988 Feb 18;318(7):404–407. doi: 10.1056/NEJM198802183180703. [DOI] [PubMed] [Google Scholar]
  15. Nemoto T., Rosner D., Diaz R., Dao T., Sponzo R., Cunningham T., Horton J., Simon R. Combination chemotherapy for metastatic breast cancer: comparison of multiple drug therapy with 5-fluorouracil, cytoxan and prednisone with adriamycin or adrenalectomy. Cancer. 1978 Jun;41(6):2073–2077. doi: 10.1002/1097-0142(197806)41:6<2073::aid-cncr2820410601>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  16. Rubens R. D., Knight R. K., Hayward J. L. Chemotherapy of advanced breast cancer: a controlled randomized trial of cyclophosphamide versus a four-drug combination. Br J Cancer. 1975 Dec;32(6):730–736. doi: 10.1038/bjc.1975.284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Sacks H. S., Berrier J., Reitman D., Ancona-Berk V. A., Chalmers T. C. Meta-analyses of randomized controlled trials. N Engl J Med. 1987 Feb 19;316(8):450–455. doi: 10.1056/NEJM198702193160806. [DOI] [PubMed] [Google Scholar]
  18. Smalley R. V., Murphy S., Huguley C. M., Jr, Bartolucci A. A. Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast. Cancer Res. 1976 Nov;36(11 Pt 1):3911–3916. [PubMed] [Google Scholar]
  19. Taylor S. G., 4th, Gelman R. S., Falkson G., Cummings F. J. Combination chemotherapy compared to tamoxifen as initial therapy for stage IV breast cancer in elderly women. Ann Intern Med. 1986 Apr;104(4):455–461. doi: 10.7326/0003-4819-104-4-455. [DOI] [PubMed] [Google Scholar]
  20. Zinser J. W., Hortobagyi G. N., Buzdar A. U., Smith T. L., Fraschini G. Clinical course of breast cancer patients with liver metastases. J Clin Oncol. 1987 May;5(5):773–782. doi: 10.1200/JCO.1987.5.5.773. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES